SCHEMBL22165533

SCHEMBL22165533

COC(=O)c1nnc(Cl)cc1Nc1ccc(OC(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.46
▸ ALDH1A1 P00352 5/20 0.46
▸ MAPT P10636 4/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ TEAD4 Q15561 1/20 0.46
▸ SYK P43405 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ P2RX3 P56373 1/20 0.41
▸ ALDH3A1 P30838 1/20 0.41
▸ IDO1 P14902 1/20 0.41
▸ TDO2 P48775 1/20 0.41
▸ AGTR1 P30556 1/20 0.40
▸ TLR9 Q9NR96 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ GAA P10253 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15091096 0.82 SYK (0.56) KMT2AALDH1A1MAPTMEN1SYK
SCHEMBL28359257 0.82 ALDH1A1 (0.47) KMT2AALDH1A1MAPTMEN1SYK
SCHEMBL29922643 0.82 ALDH1A1 (0.47) KMT2AALDH1A1MAPTMEN1SYK
SCHEMBL28362794 0.81 SYK (0.45) KMT2AALDH1A1MAPTMEN1SYK
SCHEMBL28359050 0.79 SYK (0.46) ALDH1A1SYKRAB9ANPC1ALDH3A1
SCHEMBL22165784 0.79 MAPT (0.43) KMT2AALDH1A1MAPTMEN1TEAD4
SCHEMBL29922937 0.79 SYK (0.46) KMT2AALDH1A1MAPTMEN1SYK
SCHEMBL29922768 0.79 SYK (0.46) ALDH1A1SYKRAB9ANPC1ALDH3A1
SCHEMBL29922724 0.79 SYK (0.46) KMT2AALDH1A1MAPTMEN1SYK
SCHEMBL28359009 0.79 SYK (0.46) KMT2AALDH1A1MAPTMEN1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220098203-A1 AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER LES LABORATOIRES SERVIER (FR) 2022-03-31 — — US disclosed
EP-3902804-A1 AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER Les Laboratoires Servier SAS (FR) 2021-11-03 — — EP disclosed
CN-113474347-A AZA heterobicyclic inhibitors of MAT2A and methods for treating cancer 法国施维雅药厂 2021-10-01 — — CN disclosed
WO-2020139992-A1 AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER AGIOS PHARMACEUTICALS, INC. (US) 2020-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220098203-A1 AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER MAT2A, MAT2B, MAT1A KMT2A 96/4885ALDH1A1 718/4885MAPT 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback